-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Initiates Coverage On Compass Therapeutics with Buy Rating, Announces Price Target of $10

Benzinga·12/03/2025 12:35:18
语音播报
Canaccord Genuity analyst John Newman initiates coverage on Compass Therapeutics (NASDAQ:CMPX) with a Buy rating and announces Price Target of $10.